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Abstract
Pancreatic cancer has one of the worst mortality rates of all cancers. Little is known about its etiology, particularly regarding
inherited risk. The PanScan project, a genome-wide association study, identified several common polymorphisms affecting
pancreatic cancer susceptibility. Single nucleotide polymorphisms (SNPs) in ABO, sonic hedgehog (SHH), telomerase reverse
transcriptase (TERT), nuclear receptor subfamily 5, group A, member 2 (NR5A2) were found to be associated with pancreatic
cancer risk. Moreover the scan identified loci on chromosomes 13q22.1 and 15q14, to which no known genes or other
functional elements are mapped. We sought to replicate these observations in two additional, independent populations
(from Germany and the UK), and also evaluate the possible impact of these SNPs on patient survival. We genotyped 15 SNPs
in 690 cases of pancreatic ductal adenocarcinoma (PDAC) and in 1277 healthy controls. We replicated several associations
between SNPs and PDAC risk. Furthermore we found that SNP rs8028529 was weakly associated with a better overall
survival (OS) in both populations. We have also found that NR5A2 rs12029406_T allele was associated with a shorter survival
in the German population. In conclusion, we found that rs8028529 could be, if these results are replicated, a promising
marker for both risk and prognosis for this lethal disease.
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Introduction
Pancreatic cancer is the fifth leading cause of cancer deaths in
Europe and the eighth worldwide, with a five year relative survival
of less than 5% [1]. No effective screening test for this malignancy
exists, and metastatic disease is commonly present at initial
diagnosis. Established risk factors include cigarette smoking,
obesity or overweight, a medical history of diabetes type II, and
family history of pancreatic cancer [2].
The PanScan project, a genome-wide association study
(GWAS), recently identified various pancreatic cancer susceptibil-
ity loci. Several single nucleotide polymorphisms (SNPs) in the
gene regions of ABO, sonic hedgehog (SHH), telomerase reverse
transcriptase (TERT), nuclear receptor subfamily 5, group A,
member 2 (NR5A2) were found to be associated with pancreatic
cancer risk [3]. Statistically significant associations were found also
with SNPs mapping to a region on chromosome 13q22.1 and a
region on chromosome 15q14, where no known genes are mapped
[3].
The genes to which several of the GWAS loci were mapped are
biologically plausible candidates for involvement in pancreatic
cancer. Several early studies reported an association between ABO
blood type and gastrointestinal cancers, strongest for gastric cancer
but also notable for pancreatic cancer [4,5]. SHH plays a key role
as a morphogenic factor and is related to the formation of various
malignancies, including pancreatic cancer [6]. NR5A2 encodes a
nuclear receptor of the fushi tarazu (Ftz-F1) subfamily that
interacts with b-catenin and is predominantly expressed in
exocrine pancreas, liver, intestine and ovaries in adults. The
TERT gene encodes the catalytic subunit of telomerase, essential
for maintaining telomere ends. While telomerase activity cannot
be detected in most normal tissues, it is seen in approximately 90%
of human cancers [7]. The region of chromosome 5p15.33 where
TERT maps has been identified in genome-wide association
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lung cancer, basal cell carcinoma, and melanoma. Although the
region on 13q22.1 does not contain any known gene, it is
frequently deleted in a spectrum of cancers, including pancreatic
cancer [8,9,10].
The GWAS has convincingly shown association between several
of these loci and pancreatic cancer risk. For others (SNPs in the
SHH region and in a gene desert on chromosome 15q14), it also
showed promising associations, although supported by less strong
statistical evidence [3]. Therefore, we sought to replicate these
observations in an additional, independent population of 690 cases
of pancreatic ductal adenocarcinoma (PDAC), and we evaluated
the possible impact of these SNPs on patient survival.
Materials and Methods
Ethics Statement
All participants signed an informed written consent. The study
was approved by the ethical review boards of the institutions
responsible for subject recruitment in each of the recruitment
centres. The ethical committees were the following: South West
Research Ethics Committee (Liverpool Subjects), Ethikkommis-
sion der Medizinischen Fakulta ¨t, Heidelberg (German subjects),
Ethics commitee of the University of Oxford (Oxford subjects),
Ethics commitee of the University of Cambridge (Cambridge
subjects).
Study population
Samples were collected from pancreatic cancer patients during
surgery between December 1996 and September 2009, snap-
frozen in liquid nitrogen directly after resection and subsequently
stored at 280uC.
Detailed information on the control population is given
elsewhere. Briefly, a total of 1141 healthy blood donors of
German origin were recruited in 2004 at the Institute of
Transfusion Medicine, Mannheim, Germany [11].
136 British controls were selected from people recruited in two
cohorts in EPIC, an ongoing prospective cohort being carried out
in ten European countries. The EPIC-Norfolk cohort (http://
www.srl.cam.ac.uk/epic/) comprises over 30,000 individuals, ages
45 to 75 at recruitment, resident in Norfolk, East Anglia, and
recruited from general practice registers between 1993 and 1997
[12]. The EPIC-Oxford cohort comprises 65,429 people aged 20
years and above and living in the UK recruited between 1993 and
1999 [13]. Characteristics of patients and controls are described in
Table 1.
Selection of genes and polymorphisms
We selected 15 polymorphisms that were found to be associated
with the risk of developing pancreatic cancer by a recent GWAS
[3]. In each of the six regions identified by the GWAS, we selected
the SNPs showing the strongest associations: we selected
rs12029406, rs10919791, rs3790844 in the NR5A2 gene;
rs4635969 and rs401681 for the TERT/CLPTM1L region;
rs172310, rs167020 for SHH; rs657152, rs505922, rs630014,
rs495828 for ABO; rs9543325, rs9543325 at 13q22.1; rs8028529 at
15q14. More detailed information on the selected SNPs is given in
Table 2.
DNA extraction and genotyping
DNA was extracted from frozen or paraffin-embedded
pancreatic tissues of 690 patients with resected tumors (576 from
Heidelberg, 114 from Liverpool) using the AllPrep Isolation Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Genotyping was performed using an allele-specific
PCR-based KASPar SNP genotyping system (KBiosciences,
Hoddesdon, UK) as recommended by the manufacturer. The
order of DNAs from cases and controls was randomized on PCR
plates in order to ensure that an equal number of cases could be
analyzed simultaneously. Thermocycling was performed accord-
ing to the manufacturer’s instructions. Detection was performed
using an ABI PRISM 7900 HT sequence detection system with
SDS 2.2 software (Applied Biosystems, Foster City, CA, USA).
Table 1. Characteristics of patients and healthy controls
included in this study.
German British
Cases Controls Cases Controls
N 576 1141 114 136
Gender
Female 243 324 45 55
Male 320 816 69 81
Missing 13 1 0 0
Age at diagnosis/recruitment
Mean 63.9 55.01 63.59 60.42
(standard deviation) 9.9 11.12 9.78 9.31
Median 65 58 64 61
(25%–75%) (58–71) (50–63) (57–72) (53–68)
Survival days
Mean 548.97 434.2
(standard deviation) 517.5 549.3
Median 387 305
(25%–75%) (172–750) (161.5–490)
doi:10.1371/journal.pone.0027921.t001
Table 2. SNPs genotyped and their position in the genome.
SNP Gene/Region Chromosome
Position in the
genome
rs12029406 NR5A2 1q32.1 198,172,451
rs10919791 NR5A2 1q32.1 198,231,791
rs3790844 NR5A2 1q32.1 198,274,055
rs3790843 NR5A2 1q32.1 198,277,447
rs4635969 TERT, CLPTM1L 5p15.33 1,361,552
rs401681 TERT, CLPTM1L 5p15.33 1,375,087
rs172310 SHH 7q36 155,308,388
rs167020 SHH 7q36 155,312,494
rs657152 ABO 9q34 135,129,086
rs505922 ABO 9q34 135,139,050
rs630014 ABO 9q34 135,139,543
rs495828 ABO 9q34 135,144,688
rs9543325 Gene desert 13q22.1 72,814,629
rs9564966 Gene desert 13q22.1 72,794,222
rs8028529 Gene desert 15q14 34,441,889
doi:10.1371/journal.pone.0027921.t002
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a genome-wide association study using the Human 660W-Quad
BeadChip array according to manufacturer’s instructions (Illu-
mina, San Diego, CA, USA) at Imperial College.
Statistical analysis
Hardy-Weinberg equilibrium was tested in the controls by the
chi square test. Risk analysis was performed in a total of 690
PDAC cases and 1277 healthy controls. We used logistic
regression for multivariate analyses to assess the main effects of
the genetic polymorphism on pancreatic cancer risk using a co-
dominant inheritance model. The most common allele in the
controls was assigned as the reference category. All analyses were
adjusted for age and gender.
For survival analysis, the median follow-up time was computed
with censored observations only (20%), whereas the median
survival time was calculated using data from all patients. Overall
survival (OS) was defined as the time interval between diagnosis
and death (uncensored observation) or the last date when the
patient was still alive (censored observation, medium follow up
time 1249 days). OS was evaluated using methods for censored
survival time. In particular, risk of dying was estimated by hazard
ratios (HR) and 95% confidence intervals (CI) in Cox proportional
hazard models. All the analyses were performed with STATA
software (StataCorp, College Station, TX, USA). For the survival
analysis, in order to take into account the number of tests
performed in this project, we calculated for each gene/region the
number of effective independent variables, Meff, by use of the SNP
Spectral Decomposition approach [14]. We obtained a gene-wide
Meff value for each gene and also a study-wide Meff value, by
adding up the gene Meff’s. For the replication analysis, since the
assocations had already been convincingly shown in a GWAS, a
correction for multiple testing is not necessary, therefore we used a
threshold of 0.05 to confirm our findings.
Results
In this study we sought to investigate two different endpoints:
replication of the associations between 15 GWAS SNPs and the
risk of developing pancreatic cancer, and an evaluation of the
possible associations between the same SNPs and patient survival.
We genotyped 15 SNPs in 690 cases of PDAC and 1277 healthy
controls. The average call rate was 97.20% (range 94.69%–
98.79%). For 27 cases, both normal and tumor tissues were
available and used for genotyping. No differences were observed
(398 informative genotype comparisons). Approximately 10% of
the samples were analyzed in duplicate, and the concordance rate
of the genotypes was higher than 99%. The genotype distributions
at all loci were in Hardy-Weinberg equilibrium in controls, with
non-significant chi square values (using a threshold of p,0.05,
data not shown).
The frequencies and distribution of the genotypes and the odds
ratios for the association of each polymorphism with PDAC are
described in Table S1. We were able to replicate several significant
associations between the SNPs and PDAC risk. Table 3 shows the
SNPs associated with pancreatic cancer risk in this study. The
strongest association with an increased risk of PDAC we observed
was with the C allele of the 9q34 rs9543325 SNP (ORhet 1.23,
95% CI 0.98–1.55, ORhom 1.60, 95% CI 1.14–2.25,
Ptrend=0.0023). For two SNPs in NR5A2 (rs12029406,
rs10919791), one in SHH (rs167020) and the 15q14 region SNP
(rs rs8028529) no statistically significant association was detected.
Figure S1 shows a summary of the replications in the study. Table
S1 shows the distribution of each SNP genotyped in the study and
the relative ORs in the two populations separately and together.
We investigated a possible association between the selected
SNPs and patient survival. Median survival of cases was different
in patients from Liverpool (305 days) and Heidelberg (387 days;
Cox regression test, p=10
25), therefore we conducted this analysis
separately for the two populations. The results of this analysis are
reported in Table 4 and Table S2.
We found that SNP rs8028529 (located on chromosome 15q14)
was weakly associated with a better OS in both populations. In the
German population, we found that the heterozygous carriers had a
better survival (HR=0.73, 95%CI 0.59–0.91, Pvalue=0.01,
median survival of heterozygotes=440 days, median survival of
homozygotes for the common allele=346 days), while in the
British population a better survival was observed in homozygous
carriers of the variant allele (HR=0.40, 95%CI 0.16–1.01,
P=0.05, median survival of homozygotes for the variant
allele=421 days, median survival of homozygotes for the common
allele=287 days). Analysing all samples together, adjusting by age,
gender and recruitment center, we observed that the combined
genotype (C/T + C/C) had a statistically significant association
with better survival of PDAC: HR=0.76 (95% CI 0.64–0.92)
p=0.004.
In the German population the carriers of at least one T allele of
the rs12029406 SNP, which belongs to the NR5A2 gene, showed a
shorter survival time (HR=1.23, 95%CI 1.01–1.49, P=0.04,
median survival of allele carriers=359 days). Table 4 shows the
results for these two SNPs while table S2 shows the results for all
the SNPs.
We calculated Meff values for each candidate gene/region
separately and for the whole study (by adding the individual gene
Meff values;). The study-wide Meff was 9.8. We therefore used a
study-wide significance p-threshold of 0.05/9.8=0.0051. Using
this threshold, no significant associations were observed between
any of the polymorphisms genotyped and patients survival, with
the exception of the T allele of rs8028529, in the pooled
population, with better patients survival.
Discussion
Pancreatic cancer is among the deadliest of cancers, with
mortality rates approaching incidence rates [1,15]. There is no
effective curative treatment yet for pancreatic cancer. Surgery
offers the only treatment option that significantly improves
survival. Therefore, finding genetic variants associated with disease
risk, progression and survival is of the utmost importance. Given
that there are few known risk factors, improved diagnostics and a
better understanding of the molecular pathogenesis of this disease
are urgently needed.
We report the re-evaluation of 15 SNPs found to be associated
with pancreatic cancer risk as reported in PanScan [3] and their
possible involvement in patient survival. In this study, we were
able to replicate six SNPs at a Pvalue of at least 0.05
(0.044920.0023). We could not replicate the other reported
associations, although the allelic frequencies in our study subjects
were comparable to those obtained in PanScan, and trends of risk
went in the same direction as reported by PanScan. A possible
explanation of our failure in replicating the associations may be
due to insufficient statistical power.
The most important and novel finding of this manuscript is the
fact that the C allele of SNP rs8028529, located in a gene desert on
chromosome 15q14 is associated with better survival. This
association reached statistical significance, at the conventional
0.05 threshold, in both populations we studied, although for the
Susceptibility and Survival for Pancreatic Cancer
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(C/T) carriers, while for the British cases it was observed for the
homozygous carriers of the variant allele (C/C) only. An analysis
of all samples combined, adjusting by age, gender and recruitment
center, revealed that the combined genotype (C/T + C/C) had a
statistically significant association with better survival of PDAC:
HR=0.76 (95% CI 0.64–0.92) p=0.004. In PanScan, the
association was found between the C allele and an increased risk
of pancreatic cancer. It is very difficult to understand the biological
mechanism that could explain these associations since the SNP is
located in a gene desert. The nearest gene (located at a distance of
about 500 kb) is myeloid ecotropic insertion site homeobox 2
(MEIS2), which is known to be expressed at high levels in the
pancreas and in pancreatic cancer (data from the In Silico
Transcriptomics database)[16]. This gene encodes a homeobox
protein belonging to the TALE (’three amino acid loop extension’)
family of homeodomain-containing proteins. TALE homeobox
proteins are highly conserved transcription regulators, and several
members have been shown to be essential contributors to
developmental programs. Recent studies have shown that MEIS
proteins may also be involved in tumorigenesis, although the
underlying mechanism is not yet clear [17,18]. We speculate that
the SNP could be situated in a regulatory region of the MEIS2
gene that may modify its expression and in this way alter cancer
risk and prognosis. A similar mechanism seems to be in place at
the locus on chromosome 8q24, where SNPs associated with risk
of several cancer types are located in a gene desert. Recent data
suggest that one of those SNPs can affect the binding of a
transcription factor that regulates the WNT pathway and possibly
the MYC oncogene, which maps about 1 Mb downstream [19].
In this report we have also found that the NR5A2 rs12029406_T
allele is associated with a shorter survival, although only in in the
German population. In a recent review Li and Abruzzese [20]
point out why this receptor may play a role in pancreatic cancer.
Table 3. Polymorphisms associated with pancreatic cancer risk.
Genotype Cases
a Controls
a OR
b 95% Ci
b pvalue ptrend
rs401681 | 5p15.33 | 1,375,087 | TERT, CLPTM1L
c
CC 185/661 (27.99%) 420/1267 (33.15%) 1 Ref. 0.0139
CT 336/661 (50.83%) 618/1267 (48.78%) 1.24 (0.98–1.58) 0.08
TT 140/661 (21.18%) 229/1267 (18.07%) 1.38 (1.02–1.87) 0.04
CT+TT 476/661 (72.01%) 847/1267 (66.85%) 1.28 (1.02–1.61) 0.03
rs657152 | 9q34 | 135,129,086 | ABO
c
GG 199/686 (29.01%) 437/1255 (34.82%) 1 Ref. 0.0449
GT 357/686 (52.04%) 591/1255 (47.09%) 1.26 (0.99–1.59) 0.06
TT 130/686 (18.95%) 227/1255 (18.09%) 1.27 (0.94–1.73) 0.12
GT+TT 487/686 (70.99%) 818/1255 (65.18%) 1.26 (1.01–1.58) 0.04
rs505922 | 9q34 | 135,139,050 | ABO
c
TT 205/667 (30.73%) 478/1264 (37.82%) 1 Ref. 0.0081
TC 348/667 (52.17%) 591/1264 (46.76%) 1.3 (1.03–1.64) 0.03
CC 114/667 (17.09%) 195/1264 (15.43%) 1.36 (0.99–1.86) 0.06
TC+CC 462/667 (69.27%) 786/1264 (62.18%) 1.31 (1.05–1.64) 0.02
rs495828 | 9q34 | 135,144,688 | ABO
c
GG 342/664 (51.51%) 725/1255 (57.77%) 1 Ref. 0.0215
GT 276/664 (41.57%) 450/1255 (35.86%) 1.26 (1.02–1.57) 0.04
TT 46/664 (6.93%) 80/1255 (6.37%) 1.31 (0.85–2.01) 0.23
GT+TT 322/664 (48.49%) 530/1255 (42.23%) 1.27 (1.03–1.56) 0.03
rs9543325 | 13q22.1 | 72,814,629 | Gene desert
c
TT 221/628 (35.19%) 518/1262 (41.05%) 1 Ref. 0.0023
TC 310/628 (49.36%) 601/1262 (47.62%) 1.23 (0.98–1.55) 0.08
CC 97/628 (15.45%) 143/1262 (11.33%) 1.6 (1.14–2.25) 0.01
TC+CC 407/628 (64.81%) 744/1262 (58.95%) 1.3 (1.04–1.62) 0.02
rs9564966 | 13q22.1 | 72,794,222 | Gene desert
c
GG 292/684 (42.69%) 604/1268 (47.63%) 1 Ref. 0.0079
GA 307/684 (44.88%) 549/1268 (43.3%) 1.08 (0.87–1.34) 0.48
AA 85/684 (12.43%) 115/1268 (9.07%) 1.63 (1.15–2.32) 0.01
GA+AA 392/684 (57.31%) 664/1268 (52.37%) 1.17 (0.95–1.44) 0.14
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were
resubmitted to up to two additional rounds of genotyping. Data points that were still not filled after this procedure were left blank.
bOR: odds ratio; CI: confidence interval. Adjusted for age and gender. Significant associations (p,0.05) are reported in bold.
cSNP | Chromosome | Position on chromosome (referred to NCBI build 36) | Closest gene(s).
doi:10.1371/journal.pone.0027921.t003
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contributes to diseases linked to pancreatic dysfunction, such as
diabetes. For example NR5A2 plays an important role in
transcriptional activation of the adiponectin gene [21], an
adipocyte-secreted hormone, that has been proposed to be a
biological link between obesity and increased risk of pancreatic
cancer [22]. It is interesting to note that a NR5A2 gene variant has
been associated with excess BMI in a genome-wide association
study [23]. SNPs in NR5A2, such as rs12029406, might modulate
the receptor activity which in turn can modify the disease risk and
survival.
Applying the correction for multiple testing the only association
which is lower than the study-wise threshold of 0.0051 was shown
by the combined analysis of the two populations for the T allele of
rs8028529 and better survival. The results in the two populations
are not identical, however all the HRs go in the same direction in
both populations, i.e. a protective effect of the variant allele,
although they reach statistical significance only in the heterozy-
gotes in the population from Heidelberg and only in the
homozygotes in the population from Liverpool. Indeed, by
pooling together the two populations the effect of allele remains
similar in terms of HR, but the statistical significance increases, as
it is expected by increasing the numbers of the subjects in study. It
is not immediate to explain this discrepancy: it can be that residual
confounding factors mask the associations for the heterozygotes in
the British and in the homozygotes in the Germans, or the
difference in the survival between the two populations may
contribute to masking the true association. Finally it can be that
these associations are due to chance.
These results have to be taken with caution and further
replications and functional studies are warranted. The fact that the
polymorphism is located in a vastly unexplored gene desert region
makes it difficult to really assess an immediate clinical impact for
the finding reported in this study. These results if confirmed may
prompt research on the molecular biology of the mechanism and
this can ultimately further our understanding of the disease. A
good example is the 8q24 hits, where following an original
epidemiological observation, many studies have contributed to
uncover the relationship between the SNPs of the region and the
activation of the MYC gene [19]. From this point of view our study
may be considered as a first preliminary step that could contribute
to a better understanding of the disease and, in the long term, to
the establishment of diagnostic and prognostic tools.
In conclusion, we present here the replication of six previously
associated SNPs with pancreatic cancer risk and the first evidence
of a possible involvement of rs8028529 in PDAC prognosis.
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